Abstract
A novel series of ten N-(aryl)-2-(2-methyl-1H-imidazol-1-yl)acetamides (5a-j) were synthesized by reacting 2- methylimidazole (4) with the corresponding ω- chloroacetanilides (3a-j) in Dimethly Formamide and potassium carbonate. The compounds have been characterized on the basis of elemental analysis and spectral data. All the synthesized compounds were screened for their anticonvulsant activity. Among the compounds subjected to anticonvulsant activity, compounds 5a, 5b, 5d, 5f, 5g, 5h, 5i and 5j, at a dose of 100mg/kg body weight i.p. showed significant anticonvulsant activity (p<0.01) as they delayed the onset of convulsions. The compounds 5a, 5d, 5h, 5i and 5j also decreased the duration of seizures significantly (p<0.01 and P<0.05) and the results were comparable to the diazepam treated group. Compound 5g is the most active molecule as; it increased the onset of convulsion time to nearly two fold and comparable duration of action to that of diazepam.
Keywords: 2-Methylimidazole, ω- Chloroacetanilides, Acetamides, Anticonvulsant
Letters in Drug Design & Discovery
Title:Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives
Volume: 9 Issue: 4
Author(s): Rahul Mishra, Swastika Ganguly, Kalyan Kumar Sethi, Papiya Mitra Mazumder
Affiliation:
Keywords: 2-Methylimidazole, ω- Chloroacetanilides, Acetamides, Anticonvulsant
Abstract: A novel series of ten N-(aryl)-2-(2-methyl-1H-imidazol-1-yl)acetamides (5a-j) were synthesized by reacting 2- methylimidazole (4) with the corresponding ω- chloroacetanilides (3a-j) in Dimethly Formamide and potassium carbonate. The compounds have been characterized on the basis of elemental analysis and spectral data. All the synthesized compounds were screened for their anticonvulsant activity. Among the compounds subjected to anticonvulsant activity, compounds 5a, 5b, 5d, 5f, 5g, 5h, 5i and 5j, at a dose of 100mg/kg body weight i.p. showed significant anticonvulsant activity (p<0.01) as they delayed the onset of convulsions. The compounds 5a, 5d, 5h, 5i and 5j also decreased the duration of seizures significantly (p<0.01 and P<0.05) and the results were comparable to the diazepam treated group. Compound 5g is the most active molecule as; it increased the onset of convulsion time to nearly two fold and comparable duration of action to that of diazepam.
Export Options
About this article
Cite this article as:
Rahul Mishra, Swastika Ganguly, Kalyan Kumar Sethi, Papiya Mitra Mazumder , Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives, Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799860015
DOI https://dx.doi.org/10.2174/157018012799860015 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Triheptanoin Supplementation to Ketogenic Diet Curbs Cognitive Impairment in APP/PS1 Mice Used as a Model of Familial Alzheimer’s Disease
Current Alzheimer Research Anxiety: A Systematic Review of Neurobiology, Traditional Pharmaceuticals and Novel Alternatives from Medicinal Plants
CNS & Neurological Disorders - Drug Targets The Synthesis and Evaluation of Novel Lactate Dehydrogenase Nanobioconjugates
Current Nanoscience NMDA Receptors are not Alone: Dynamic Regulation of NMDA Receptor Structure and Function by Neuregulins and Transient Cholesterol-Rich Membrane Domains Leads to Disease-Specific Nuances of Glutamate- Signalling
Current Topics in Medicinal Chemistry Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Is Mania the Hypertension of the Mood? Discussion of A Hypothesis
Current Neuropharmacology Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) NLRP3 Inflammasome Activation Leads to Epileptic Neuronal Apoptosis
Current Neurovascular Research Integrating Virtual Screening Methods to the Quest for Novel Membrane Protein Ligands
Current Medicinal Chemistry - Central Nervous System Agents Neurotoxic and Neuroactive Compounds from Cnidaria: Five Decades of Research….and More
Central Nervous System Agents in Medicinal Chemistry Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Targeting BLyS in Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling
Current Neuropharmacology Occurrence of DAT1 (VNTR) Polymorphism in Individuals with HIV Infection
Current Pharmacogenomics and Personalized Medicine TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Natural AChE Inhibitors from Plants and their Contribution to Alzheimer’s Disease Therapy
Current Neuropharmacology A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare? How the Neurophenomenology of Psychedelics Research Could Help us to Flourish Throughout Our Lives, as Well as to Enhance Our Dying
Current Drug Abuse Reviews Editorial Review 2015
Current Radiopharmaceuticals Endophenotypes and Biological Markers of Schizophrenia: From Biological Signs of Illness to Novel Treatment Targets
Current Pharmaceutical Design